Multi-fraction SABR

RADIATION2 trials

Sponsors

Trans Tasman Radiation Oncology Group, University of Sydney

Conditions

CancerMetastases to the LungProstate Cancer

Unknown Phase

A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)

CompletedNCT01965223

Trans Tasman Radiation Oncology GroupCancer, Metastases to the Lung

Start: 2015-02-04End: 2020-07-27Updated: 2020-11-04

Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring

CompletedNCT02397317

University of SydneyProstate Cancer

Start: 2016-02-01End: 2020-06-19Updated: 2026-05-19

Related Papers

The TROG 15.01 stereotactic prostate adaptive radiotherapy utilizing kilovoltage intrafraction monitoring (SPARK) clinical trial database

Medical Physics2024-11-233 citations

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II)

JAMA Oncology2021-08-2984 citations

Is multileaf collimator tracking or gating a better intrafraction motion adaptation strategy? An analysis of the TROG 15.01 stereotactic prostate ablative radiotherapy with KIM (SPARK) trial.

2020-08-2012 citations

Stereotactic prostate adaptive radiotherapy utilising kilovoltage intrafraction monitoring: the TROG 15.01 SPARK trial.

2017-03-0836 citations

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)

BMC Cancer2016-03-0443 citations